fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Jason McCarthy, Ph.D. Maxim Group

By John F. Heerdink, Jr. LinkedIn
[social_share_button themes='theme8']
 

Jason McCarthy, Ph.D.

Biotechnology Equity Analyst at Maxim Group

View Linkedin Profile

“Atossa has multiple catalysts across several clinical programs coming over the next 12-18 months Both the topical and oral formulations of endoxifen continue to advance and management is executing on its clinical strategy. Catalysts lay ahead as data emerges from ongoing and upcoming studies, which if positive should drive a higher valuation.”


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us